Moexipril: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{CMG}} | {{CMG}} | ||
===[[Moexipril hydrochloride|Moexipril hydrochloride]] ([[Univasc]] | ===[[Moexipril hydrochloride|Moexipril hydrochloride]] ([[Univasc]])=== | ||
===[[Moexipril hydrochloride/Hydrochlorothiazide|Moexipril hydrochloride/Hydrochlorothiazide]] ([[Dutoprol]])=== | ===[[Moexipril hydrochloride/Hydrochlorothiazide|Moexipril hydrochloride/Hydrochlorothiazide]] ([[Dutoprol]])=== | ||
==Overview== | ==Overview== | ||
Revision as of 20:57, 23 July 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Moexipril hydrochloride (Univasc)
Moexipril hydrochloride/Hydrochlorothiazide (Dutoprol)
Overview
Moexipril Hydrochloride is an angiontensin converting enzyme inhibitor that is FDA approved for the treatment of hypertension. Adverse reactions include diarrhea, dizziness, cough and Influenza-like symptoms abnormal.
The active substance metoprolol is employed either as Moexipril hydrochloride or as Moexipril hydrochloride and hydrochloridethiazide.
Category
Angiontensin converting enzyme inhibitor